Payment overview · 2025
General Payments
$525.87
26 reported records · 18 companies
Healthcare provider profile · identity verified
Joseph Winchell, MD
Allopathic & Osteopathic Physicians|Family Medicine · PICKERINGTON, OH · NPI 1598706632
Verified facts
What the public records show
CMS Open Payments records show Joseph Winchell, MD received $525.87 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 14.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Synthroid, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.59 | 14.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.40 | 12.4% | 4 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $34.12 | 6.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.04 | 6.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.65 | 6.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.61 | 5.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.23 | 4.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.20 | 4.6% | 1 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $24.20 | 4.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.21 | 4.4% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.94 | 4.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.43 | 4.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $21.72 | 4.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.66 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.69 | 3.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.49 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.00 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.69 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.87 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.65 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.65 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.37 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $34.12 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.04 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.23 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 65 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 770 | 229 |
| Lisinopril | Lisinopril | 508 | 147 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 290 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 86 |
| Losartan Potassium | Losartan Potassium | 237 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 78 |
| Omeprazole | Omeprazole | 206 | 62 |
| Gabapentin | Gabapentin | 192 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 53 |
| Simvastatin | Simvastatin | 180 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 177 | 54 |
| Metformin Hcl | Metformin Hcl | 170 | 53 |
| Ozempic | Semaglutide | 139 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 134 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 124 | 45 |
| Eliquis | Apixaban | 119 | 35 |
| Mirtazapine | Mirtazapine | 119 | 43 |
| Mounjaro | Tirzepatide | 108 | 23 |
| Ezetimibe | Ezetimibe | 105 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 98 | 18 |
| Metformin Hcl Er | Metformin Hcl | 98 | 34 |
| Trazodone Hcl | Trazodone Hcl | 96 | 30 |
| Carvedilol | Carvedilol | 92 | 28 |
| Alprazolam | Alprazolam | 86 | 17 |
| Potassium Chloride | Potassium Chloride | 86 | 28 |
| Bupropion Xl | Bupropion Hcl | 84 | 27 |
| Spironolactone | Spironolactone | 81 | 31 |
| Meloxicam | Meloxicam | 79 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 71 | 20 |
| Montelukast Sodium | Montelukast Sodium | 70 | 23 |
| Sertraline Hcl | Sertraline Hcl | 70 | 28 |
| Jardiance | Empagliflozin | 69 | 19 |
| Chlorthalidone | Chlorthalidone | 68 | 23 |
| Allopurinol | Allopurinol | 66 | 21 |
| Atenolol | Atenolol | 66 | 19 |
| Synthroid | Levothyroxine Sodium | 65 | 16 |
| Trulicity | Dulaglutide | 64 | 12 |
| Furosemide | Furosemide | 61 | 24 |
| Glimepiride | Glimepiride | 56 | 16 |
| Lorazepam | Lorazepam | 56 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Tramadol Hcl | Tramadol Hcl | 53 | 18 |
| Prednisone | Prednisone | 52 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 20 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 17 |
| Alendronate Sodium | Alendronate Sodium | 44 | 15 |
| Finasteride | Finasteride | 44 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 38 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Baclofen | Baclofen | 34 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 33 | 12 |
| Famotidine | Famotidine | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 14 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 13 |
| Estradiol | Estradiol | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 12 |
| Dutasteride | Dutasteride | 18 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Novofine 32 | Pen Needle, Diabetic | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Xyosted | Testosterone Enanthate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.87 · 26 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Adzenys XR-ODT, Azstarys, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, JOURNAVX, KRYSTEXXA, Kerendia, Korlym, LEQVIO, NEXLETOL, NURTEC ODT, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SYNTHROID, Tlando, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error